帕比司他作为复发难治性多发性骨髓瘤患者治疗选择的潜力。
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
作者信息
Andreu-Vieyra Claudia V, Berenson James R
机构信息
Oncotherapeutics, West Hollywood, CA, USA.
Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA 90069, USA.
出版信息
Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614.
Abstract
Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.
摘要
帕比司他是一种处于研究阶段的强效组蛋白去乙酰化酶抑制剂（HDACi），在临床前研究中已显示出作为抗多发性骨髓瘤药物的潜力。在本综述中，我们讨论了将帕比司他用作多发性骨髓瘤联合治疗药物的理论依据，并概述了近期及正在进行的测试帕比司他治疗该疾病安全性和有效性的临床试验。
相似文献
1
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614.
2
Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Drugs Today (Barc). 2015 Aug;51(8):491-504. doi: 10.1358/dot.2015.51.8.2362311.
3
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Expert Rev Anticancer Ther. 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7.
4
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):752-765. doi: 10.1016/j.clml.2021.06.020. Epub 2021 Jun 26.
5
Panobinostat for the treatment of multiple myeloma: the evidence to date.
J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015.
6
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.
Onco Targets Ther. 2016 May 10;9:2783-93. doi: 10.2147/OTT.S87962. eCollection 2016.
7
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
J Oncol Pharm Pract. 2019 Apr;25(3):613-622. doi: 10.1177/1078155218788706. Epub 2018 Jul 31.
8
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Oncologist. 2018 May;23(5):631-636. doi: 10.1634/theoncologist.2017-0301. Epub 2017 Nov 30.
9
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26.
10
Deacetylase inhibitors: an advance in myeloma therapy?
Expert Rev Hematol. 2017 Mar;10(3):229-237. doi: 10.1080/17474086.2017.1280388. Epub 2017 Feb 1.
引用本文的文献
1
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.
Int J Mol Sci. 2024 Feb 8;25(4):2060. doi: 10.3390/ijms25042060.
2
The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.
Int J Mol Sci. 2022 Dec 10;23(24):15671. doi: 10.3390/ijms232415671.
3
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
Front Chem. 2022 Aug 12;10:948217. doi: 10.3389/fchem.2022.948217. eCollection 2022.
4
Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Hematol Oncol. 2022 Dec;40(5):999-1008. doi: 10.1002/hon.3045. Epub 2022 Jul 14.
5
Multiple Myeloma: Possible Cure from the Sea.
Cancers (Basel). 2022 Jun 16;14(12):2965. doi: 10.3390/cancers14122965.
6
Co-Delivery of CPT-11 and Panobinostat with Anti-GD2 Antibody Conjugated Immunoliposomes for Targeted Combination Chemotherapy.
Cancers (Basel). 2020 Oct 31;12(11):3211. doi: 10.3390/cancers12113211.
7
Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis.
Int J Mol Sci. 2020 Sep 7;21(18):6521. doi: 10.3390/ijms21186521.
8
Temporal expression of MOF acetyltransferase primes transcription factor networks for erythroid fate.
Sci Adv. 2020 May 20;6(21):eaaz4815. doi: 10.1126/sciadv.aaz4815. eCollection 2020 May.
9
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Invest New Drugs. 2020 Aug;38(4):1108-1116. doi: 10.1007/s10637-019-00864-7. Epub 2019 Oct 25.
10
Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.
Ann Hematol. 2019 Nov;98(11):2569-2578. doi: 10.1007/s00277-019-03797-6. Epub 2019 Oct 18.
本文引用的文献
1
Cancer statistics, 2014.
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
2
Predicting response to epigenetic therapy.
J Clin Invest. 2014 Jan;124(1):47-55. doi: 10.1172/JCI69737. Epub 2014 Jan 2.
3
New and emerging HDAC inhibitors for cancer treatment.
J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2.
4
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430.
5
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Cell Death Dis. 2013 Oct 24;4(10):e878. doi: 10.1038/cddis.2013.406.
6
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Ann Hematol. 2014 Jan;93(1):89-98. doi: 10.1007/s00277-013-1910-2. Epub 2013 Oct 18.
7
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Semin Oncol. 2013 Oct;40(5):634-51. doi: 10.1053/j.seminoncol.2013.07.007.
8
Novel generation of agents with proven clinical activity in multiple myeloma.
Semin Oncol. 2013 Oct;40(5):618-33. doi: 10.1053/j.seminoncol.2013.07.005.
9
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
BMC Cancer. 2013 Oct 2;13:450. doi: 10.1186/1471-2407-13-450.
10
Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Cancer Chemother Pharmacol. 2013 Nov;72(5):935-52. doi: 10.1007/s00280-013-2223-9. Epub 2013 Sep 14.
Zotero 插件